Genocea Biosciences

Genocea Biosciences

Harnessing the power of T cells.

Human health & social work | Global | Access to Information |

 Profile Provided By: Company Website

Overview

Genocea finds targets of T cell responses to discover and develop life changing medicines.We ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.Genocea's pipeline of novel T cell vaccines includes GEN 003 for HSV 2 therapy and GEN 004 a protein vaccine directed at pneumococcus both currently in Phase II clinical trials.

Industry

Legal Structure

Operating Status

Employees

Human health & social work Operating 51 - 200 employees

Funding and Financing Rounds


Team


Impact

Geographies:

Social Objectives:

Environmental Objectives:

Operational Impact:


Impact Reports & Metrics


Offices

Headquarters

100 Acorn Park Drive Floor 5
Cambridge, Massachusetts 02140
United States of America



Explore

Revision History

Last Update: Oct 07, 2017 8:45 p.m.

Quick Search



  • Global  
  • Africa  
  • Americas  
  • Asia  
  • Europe  
  • Oceania  


News & Links

Incoming

Twitter

Tweet from Genocea: It’s not just a fashion statement, we #wearwhite today to show our support for @CancerResearch and the fight to fin… https://t.co/NvWwnnqZdR Posted Fri Jun 15 10:27 am

Tweet from Genocea: Wondering why we're so excited about neoantigens? Dr. Wendy Broom, Director of Discovery at $GNCA, will be present… https://t.co/tDanN77Db1 Posted Fri May 18 8:36 am

Tweet from Genocea: Learn more about our inspiring CEO @TheChipClark and the turnaround story of @GenoceaBio in ep. 19 of #thelongrun p… https://t.co/G3tKBpSzct Posted Mon May 14 10:54 am

Tweet from Genocea: https://t.co/DCRkXHb9Qy https://t.co/42KyuLpnCz Posted Mon Apr 30 1:11 pm

Tweet from Genocea: $GNCA is gearing up for Phase 1/2a testing the safety, immunogenicity, and clinical efficacy of GEN-009 after filing our IND! #targetsmatter Posted Mon Apr 30 6:00 am

Tags

COPYRIGHT 2018 IMPACTSPACE. ALL RIGHTS RESERVED.